

CONTAGIOUS AGALACTIA

SUMMARY

Contagious agalactia is a serious disease syndrome of sheep and goats that is characterised by mastitis, arthritis, keratoconjunctivitis and, occasionally, abortion. Mycoplasma agalactiae is the main cause of the disease in sheep and goats, but M. capricolum subsp. capricolum (Mcc), M. mycoides subsp. capri (Mmc) (formerly named M. mycoides subsp. mycoides LC [LC = large colonies]) and M. putrefaciens produce a clinically similar disease, more often in goats, which may be accompanied by pneumonia. Antibodies to Mmc and Mcc have been detected in South American camelids (alpacas, llamas and vicunas), but no mycoplasmas have yet been isolated.

Identification of the agent: *Definitive diagnosis requires the isolation of the causative mycoplasmas from the affected animals, which are then identified by biochemical, serological and, increasingly, molecular tests such as the polymerase chain reaction. Samples of choice include milk, conjunctival and ear swabs, and joint fluid. All four mycoplasmas grow relatively well in most mycoplasma media although M. agalactiae shows a preference for organic acids such as pyruvate as substrates.*

Serological tests: *Detection of antibodies in serum by complement fixation test or enzyme-linked immunosorbent assay (ELISA) provides rapid diagnosis of disease, but may not be very sensitive in chronically affected herds and flocks. Indirect ELISAs have been used routinely in control programmes for screening herds for M. agalactiae. Confirmation of infection by isolation and identification is usually necessary in areas believed to be free of contagious agalactia. Serological tests are not widely available for M. putrefaciens.*

Requirements for vaccines and diagnostic biologicals: *Commercial vaccines for M. agalactiae, inactivated with formalin, are widely used in southern Europe, but are not considered to be very efficacious. Under experimental conditions, M. agalactiae vaccines inactivated with saponin or phenol have been shown to be more protective than formalised preparations. Live vaccines for M. agalactiae are used in Turkey, where they are reported to be more protective than inactivated vaccines. A commercial vaccine containing M. agalactiae, Mmc and Mcc is available. Autogenous vaccines for Mmc and, occasionally, for Mcc are believed to be used in some countries. No vaccines exist for M. putrefaciens, as the disease it causes is not considered to be sufficiently serious or widespread.*

A. INTRODUCTION

Contagious agalactia is a disease of sheep and goats that is characterised by mastitis, arthritis and keratoconjunctivitis, and has been known for nearly 200 years. It occurs in Europe, western Asia, the United States of America (USA) and North Africa, and is mainly caused by *Mycoplasma agalactiae* (3). In recent years, *M. capricolum* subsp. *capricolum* (Mcc) and *M. mycoides* subsp. *capri*¹ (formerly *M. mycoides* subsp. *mycoides* LC [LC = large colonies]) have also been isolated in many countries from sheep and goats with mastitis and arthritis. The clinical signs of these infections are sufficiently similar to be considered indistinguishable from contagious agalactia. In addition, *M. putrefaciens* also causes mastitis and arthritis in goats, which is very similar to that caused by *M. agalactiae*, Mmc and Mcc (25). Furthermore, the consensus of the working group on

¹ International Committee on Systematics of Prokaryotes Subcommittee on the Taxonomy of Mollicutes has proposed the merging of these two subspecies into the single subsp: *M. mycoides* subsp. *capri*; a decision is pending.

contagious agalactia of the EC COST² Action 826 on ruminant mycoplasmoses, which met in Toulouse, France, in 1999, was that all four mycoplasmas should be considered as causal agents of contagious agalactia.

Clinically, the disease caused by *M. agalactiae* is recognised by elevated temperature, inappetence and alteration in the consistency of the milk in lactating ewes with decline and subsequent failure of milk production, often within 2–3 days, as a result of interstitial mastitis (3); lameness and keratoconjunctivitis affects about 5–10% of infected animals. Fever is common in acute cases and may be accompanied by nervous signs, but both signs are rare in the more frequently observed subacute and chronic infections. Pregnant animals may abort. *Mycoplasma agalactiae* may occasionally be found in lung lesions (14), but pneumonia is not a consistent finding. Bacteraemia is common, particularly for *Mmc* and *Mcc* and could account for the isolation of the organism from sites where it is only transiently present.

Mastitis, arthritis, pleurisy, pneumonia, and keratoconjunctivitis may all result from infection with *Mmc*, which has one of the widest geographical distribution of ruminant mycoplasmas, being found on all continents where small ruminants are kept and wherever contagious agalactia and caprine pleuropneumonia are reported (6, 18); however the lack of diagnostic facilities for mycoplasma diseases in many countries means that it is probably under reported. *Mmc* is mostly confined to goats but has occasionally been isolated from sheep with reproductive disease and cattle with arthritis or respiratory disease. Cases usually occur sporadically, but the disease may persist and spread slowly within a herd. After parturition, the opportunity for spread in milking animals increases, and kids ingesting infected colostrum and milk become infected. The resulting septicaemia, with arthritis and pneumonia, causes high mortality in kids (3, 6).

Mcc is widely distributed and highly pathogenic, particularly in North Africa but the frequency of occurrence is low (3). Goats are more commonly affected than sheep, and clinical signs of fever, septicaemia, mastitis, and severe arthritis may be followed rapidly by death (3, 4). Pneumonia may be seen at necropsy. The severe joint lesions seen in experimental infections with this organism are accompanied by intense periarticular subcutaneous oedema affecting tissues some distance from the joint (4).

Mycoplasma putrefaciens is common in milking goat herds in western France where it can be isolated from animals with and without clinical signs (15). It has also been associated with a large outbreak of mastitis and agalactia leading to severe arthritis in goats accompanied by abortion and death without pyrexia in California, USA (3). *Mycoplasma putrefaciens* was the major finding in an outbreak of polyarthritis in kids in Spain (25).

Antibodies to *Mmc* and *Mcc*, but not *M. agalactiae*, have been detected in South American camelids, including llamas, alpacas and vicunas, but as yet no mycoplasmas have been isolated (17). These camelids are affected by a range of mycoplasma-like diseases, including polyarthritis and pneumonia, so it is likely that mycoplasmas including *Mmc* and *Mcc* may be found in the future.

B. DIAGNOSTIC TECHNIQUES

1. Identification of the agents

a) Selection of samples

Preferred samples from living animals include: nasal swabs and secretions; milk from mastitic females or from apparently healthy females where there is a high rate of mortality/morbidity in kids; joint fluid from arthritic cases; conjunctival swabs from cases of ocular disease; and blood for antibody detection from affected and non-affected animals (19). The ear canal has also been shown to be a source of pathogenic mycoplasmas, although in practice the presence of nonpathogenic mycoplasmas at this site may make confirmation difficult (19). Mycoplasmas may be isolated from the blood during the acute stage of the disease when there is mycoplasmaemia. From dead animals, samples should include: udder and associated lymph nodes, joint fluid, lung tissue (at the interface between diseased and healthy tissue) and pleural/pericardial fluid. Samples should be dispatched quickly to a diagnostic laboratory in a moist and cool condition. All four causative mycoplasmas are relatively easy to isolate from internal organs, joints and milk and grow well in most mycoplasma media, producing medium to large colonies in 3–4 days.

b) *Mycoplasma medium*

The usual techniques used in the isolation of mycoplasmas apply to all four causative organisms (19). Many media have been reported to grow the causative mycoplasmas. Improved growth rates of *M. agalactiae* have been seen in media containing organic acids such as pyruvate and isopropanol (12). The formulation of PRM medium (12) is as follows:

2 European Cooperation in the field of Scientific and Technical Research.

Heat inactivated porcine serum 100 ml/litre, special peptone 20 g/litre, yeast extract 5 g/litre, glycerol 5 g/litre, sodium chloride 5 g/litre, HEPES 9 g/litre, fresh yeast extract 100 ml/litre, sodium pyruvate 5 g/litre, 12.5 ml of 0.2% phenol red and ampicillin (200,000 International Units/ml. Make up to 1 litre in distilled water and sterilise by filtration. Adjust the pH of the broth medium to 7.6. Prepare solid medium by adding 10 g of LabM agar No. 1 (Bury UK, or agar of equivalent quality) and dispense into sterile Petri dishes.

Thallium acetate (250 mg/litre), which is toxic and inhibitory to some mycoplasmas but not those causing contagious agalactia, may be a necessary component of the transport medium to reduce bacterial contamination from clinical samples, but should be omitted once the mycoplasmas begin to grow *in vitro*. A satisfactory alternative to thallium acetate may be colistine sulphate (37.5 mg/litre).

• **Test procedure**

- i) Make tenfold dilutions (10^1 – 10^6) of the liquid sample (milk, synovial fluid, conjunctival and ear swabs) or tissue homogenate in appropriate broth medium.
- ii) Spread a few drops of each sample on the agar medium and dispense a 10% (v/v) inoculum into broth medium.
- iii) Streak swabs directly on to agar medium.
- iv) Incubate inoculated broths (optimally with gentle shaking) and agar media at 37°C in humidified atmosphere with 5% carbon dioxide.
- v) Examine broths daily for signs of growth (indicated by a fine cloudiness or opalescence) or changes in pH indicated by a colour change and examine agar media under $\times 35$ magnification for typical 'fried egg' colonies.
- vi) If no mycoplasma growth is seen after 7 days, subculture a 10% (v/v) inoculum of broth into fresh broth and spread about 50 μ l of this on to agar media.
- vii) Repeat as for step v. If no mycoplasmas are seen after 21 days' incubation, consider the results to be negative.
- viii) If bacterial contamination results (seen as excessive turbidity), filter sterilise by passing 1 ml of contaminated broth through a 0.45 μ m filter into fresh broth medium.

Clinical samples frequently contain more than one mycoplasma species so clone purification of colonies is often considered necessary before performing biochemical and serological identification, in particular the growth and film inhibition tests (GIT and FIT, respectively). However, cloning is a lengthy procedure taking at least 2 weeks. The immunofluorescence test (5), dot immunobinding tests (21) and, more recently, polymerase chain reaction (PCR) tests (see Section B.1.e) do not require cloning as these tests can detect the pathogenic mycoplasmas in mixed cultures, saving a great deal of time.

c) Biochemical tests

The first test that should be performed on the cloned isolates is sensitivity to digitonin, which separates mycoplasmas from acholeplasmas; the latter are ubiquitous contaminants that can overgrow the mycoplasmas of interest. Growth in liquid medium containing glucose (1%), arginine (0.2%), and phenolphthalein diphosphate (0.01%), on solid medium containing horse serum or egg yolk for the demonstration of film and spots, and on casein agar or coagulated serum agar to test for proteolysis, are among the most useful tests for differentiating the four mycoplasmas (22). These biochemical characteristics, however have been increasingly found to be variable for the individual mycoplasmas and have little diagnostic value. The most impressive biochemical characteristic that differentiates *M. putrefaciens* from all other mycoplasmas is the odour of putrefaction it produces in broth culture. Other features that may be helpful include: film and spot production seen on the surface of the broth and solid media caused by *M. agalactiae* and to a lesser extent by *M. putrefaciens*; and the proteolytic activity of *Mcc* and *MmmLC* on casein and coagulated serum.

A rapid and highly convenient biochemical test that exploits the C8-esterase activity of *M. agalactiae* has been reported (11). The mycoplasma forms red colonies on agar media within 1 hour of adding the chromogenic substrate, SLPA-octanoate (a newly synthesised ester formed from a C8 fatty acid and a phenolic chromophore). This activity is shared with *M. bovis*, although this mycoplasma is rarely found in small ruminants. Isolates need not be cloned as *M. agalactiae* can be detected easily in mixed cultures. If necessary PCRs can be used to distinguish rapidly *M. agalactiae* from *M. bovis* (see Section B.1.e).

d) Serological identification

Identification of isolates using specific antisera is usually carried out with the GIT, FIT (23) or the indirect fluorescent antibody (IFA) test (5). A recently developed dot immunobinding test, which is carried out in microtitre plates, offers many improvements over the other serological tests such as rapidity and higher throughputs (21) but requires subjective judgements of staining intensity. For *M. agalactiae*, film inhibition

may often be more reliable as growth inhibition is not seen with all isolates; it can also be used for serodiagnosis. Film production by the mycoplasma may be enhanced by the incorporation of 10% egg yolk suspension into the solid medium.

- **Test procedure**

- i) Inoculate at least two dilutions of 48-hour cloned broth cultures (10^{-1} and 10^{-2}) on to predried agar media by allowing 50 μ l of the cultures to run down the tilted plates using the 'running drop' technique (23). Remove any excess liquid with a pipette.
- ii) Allow the plates to dry. It is possible to apply two or three well separated running drops to each 90 mm diameter plate.
- iii) Apply predried filter paper discs containing 30 μ l of specific antiserum to the culture; ensure good separation of discs (at least 30 mm).
- iv) Incubate the plates as for mycoplasma culture and examine daily by eye against a light background.

- **Interpretation of the results**

A zone of inhibition over 2 mm, measured from the paper disc to the edge of mycoplasma growth is considered to be significant. Partial inhibition can occur with weak antiserum or where there are mixed cultures. Stronger reactions can be obtained if about 60 μ l of antisera is added to 6 mm diameter wells made in the agar with a cork borer or similar device (23).

In the IFA test, specific antisera are applied to colonies on solid medium. Homologous antiserum remains attached after washing and is demonstrated by adding fluorescein-conjugated antiglobulin, washing, and viewing the colonies with an epifluorescence microscope (5). Controls should include known positive and known negative control organisms, and a negative control serum. However like the immunobinding tests subjective judgements are required to assess staining intensity.

Antisera for these serological tests have traditionally been prepared against the type strains of the various *Mycoplasma* species, and most field isolates have been readily identified using these antisera. As more strains have been examined, however, some have been found to react poorly with these antisera, while reacting well with antisera to other representative strains of the species. Intraspecies variation in antigenic composition has not been reported for *M. putrefaciens*, but occurs to some degree with *M. agalactiae* and with *Mcc* strains. Thus, diagnostic laboratories may need to have several antisera to enable all strains of the species to be identified.

e) Nucleic acid recognition methods

PCR assays are routinely used in many laboratories and are extremely sensitive. They can provide a rapid early warning system when carried out on clinical samples, enabling a full investigation to take place when results are positive. However negative results should not be considered definitive. Several PCRs specific for *M. agalactiae* have been developed and show similar levels of sensitivity, although they are based on different gene sequences (1, 7, 26, 28). They can be used directly on nasal, conjunctival, synovial and tissue samples; they have been used on milk samples where they have been reported to be more sensitive than culture (28), although occasionally undefined inhibitors may interfere with the test. PCRs can also be used, more reliably, on mycoplasmas growing in culture; a 24 hour enrichment of the mycoplasma in the appropriate medium greatly facilitates PCR detection even in the presence of bacterial contamination (18). A newly described PCR based method called denaturing gradient gel electrophoresis (DGGE) that uses mycoplasma-specific primers is capable of identifying the majority of small ruminant mycoplasmas including all the causative agents of contagious agalactia by their migration pattern (16). A positive PCR result, particularly in an area previously free of contagious agalactia, should be confirmed by isolation and identification of the mycoplasma using standard procedures.

Individual PCRs have been reported for *Mmc* and *Mcc* (2) and *M. putrefaciens* (20) respectively. In addition a multiplex test has been described which can detect simultaneously *M. agalactiae*, *Mcc* and *Mmc* (9).

- **Test procedure**

The following primers based on the *uvrC* gene have been shown to be specific for *M. agalactiae* (26). PCRs may need to be optimised in each laboratory. Positive and negative control DNA should be run in each assay.

MAGAUVRC1-L CTC-AAA-AAT-ACA-TCA-ACA-AGC

MAGAUVRC1-R CTT-CAA-CTG-ATG-CAT-CAT-AA

- i) Extract DNA from *Mycoplasma* isolates or clinical material using the appropriate method (4).
- ii) Carry out PCR methods in 50 µl reaction mixtures containing: 1 µl of sample DNA, 20 pmol of each primer (see above), 1 mM each dNTP, 10 mM Tris/HCl, pH 8.3, 1.5 mM MgCl₂, 50 mM KCl and 1.25 mM U *Taq* DNA polymerase.
- iii) Subject the mixture to 35 amplification cycles in a thermal cycler with the following parameters: 30 seconds at 94°C, 30 seconds at 50°C annealing temperature and 1 minute at 72°C.
- iv) Analyse the PCR products by electrophoresis on a 0.7% agarose at 110 V for 2 hours and visualise by staining with ethidium bromide. A 1.7 kb fragment indicates the presence of *M. agalactiae*.

2. Serological tests

a) Complement fixation

A standard complement fixation test (CFT) for *M. agalactiae* has also been applied to other mycoplasmas involved in the contagious agalactia syndrome (3). Antigens are prepared from washed organisms, standardised by opacity, and lysed, either ultrasonically or by using sodium lauryl sulphate followed by dialysis. Sera are inactivated at 60°C for 1 hour, and the test is carried out in microtitre plates with overnight fixation in the cold or at 37°C for 3 hours. The haemolytic system is added, and the test is read after complete lysis is shown by the antigen control. A positive result is complete fixation at a serum dilution of 1/40 or greater for the following mycoplasmas: *M. agalactiae*, *Mcc*, and *Mmc*. The CFT is regarded as a herd test and at least ten sera are tested from each herd, preferably from acute and convalescent cases.

Some sera from healthy flocks react in the CFT using *M. agalactiae* up to a serum dilution of 1/20, but rarely react with the other two antigens. However, in flocks infected with *M. agalactiae*, sera giving a homologous reaction at 1/80 may cross-react at up to 1/40, the positive threshold, with the other two antigens. It is often difficult to perform the CFT if the quality of the test sera is poor; where possible, the enzyme-linked immunosorbent assay (ELISA) is preferred.

b) Enzyme-linked immunosorbent assay

ELISAs using sonicated or Tween-20-treated antigens have been reported to be more sensitive than the CFT for the detection of antibody to *M. agalactiae* (3). Problems of nonspecificity have been overcome by the use of monoclonal or protein G conjugates in the ELISA (13). The use of these conjugates enables the testing of sera from a wide range of mammalian species, including camelids. A number of commercial ELISA kits are now available and these are being used for large-scale surveys in France and the United Kingdom (3, 17). In a ring trial of serological tests for *M. agalactiae* organised in 1998 under the auspices of the EC COST Action 826 on ruminant mycoplasmoses, commercial ELISAs performed better than 'home-made' kits.

ELISAs are not widely available for the other three causative mycoplasmas although 'home-made' assays are carried out by some laboratories.

c) Immunoblotting test

Immunoblotting tests have been reported as the most sensitive and specific test for *M. mycoides* subsp. *mycoides* SC, the cause of contagious bovine pleuropneumonia (see Chapter 2.4.9). Immunoblotting tests have also been described for *M. agalactiae* (17, 29). Strong bands at approximately 80 and 55 kDa were seen with sera with antibodies to *M. agalactiae*, while sera from healthy flocks show no bands or very faint bands of different sizes. Diluting the sera to 1/50 improves the discrimination between positive and negative sera (17).

C. REQUIREMENTS FOR VACCINES AND DIAGNOSTIC BIOLOGICALS

Vaccines for the prevention of contagious agalactia due to *M. agalactiae* are used widely in the Mediterranean countries of Europe and in western Asia. No single vaccine has been universally adopted, and no standard methods of preparation and evaluation have been applied.

1. Vaccines for *Mycoplasma agalactiae* infection

a) Inactivated vaccines for *Mycoplasma agalactiae* infection

In Europe, where live vaccines for *M. agalactiae* are not acceptable, attention has focused on the use of killed organisms, mostly using formalin and an adjuvant such as aluminium hydroxide in an oil emulsion. The titres of the preparations, before inactivation, are very high (10^8 – 10^{10} colony-forming units per ml) and are derived from laboratory strains. Some products are available commercially including a trivalent preparation containing *M. agalactiae*, *Mcc* and *Mmc* but there are few data on their efficacy. A formalin-inactivated oil

emulsion vaccine was shown to be immunogenic and protective in a small trial in lactating sheep and also prevented transmission of *M. agalactiae* (8).

It is possible that in some instances the apparent lack of protection given by vaccines could be the result of animals being infected with one of the other four mycoplasmas involved in the contagious agalactia syndrome (10). A multivalent formalin inactivated vaccine incorporating all four causative mycoplasmas and adjuvanted with saponin and aluminium hydroxide appears beneficial in preliminary trials (24).

More recently vaccines inactivated with phenol or with saponin have given superior protection against experimental infections compared with formalin, sodium hypochlorite or heat-inactivated vaccines (30).

b) Live attenuated vaccines for *Mycoplasma agalactiae* infection

Live attenuated vaccines against *M. agalactiae* have been used in Turkey for many years and have been reported to provide better protection in ewes and their lambs than inactivated vaccines (18). However they can produce a transient infection with shedding of mycoplasma. Live vaccines should not be used in lactating animals and should be part of a regional plan in which all flocks from which animals are likely to come into contact be vaccinated at the same time.

2. Vaccines for *Mycoplasma mycoides* subsp. *capri* infection

There is little recent published information on the availability of vaccines for *Mmc* although it is believed that inactivated vaccines are widely used in many Mediterranean countries and in Asia suggesting that their production and use is localised (3). Saponised vaccines have been reported in India which provoke a strong antibody response and show some protection (27).

3. *Mycoplasma capricolum* subsp. *capricolum* and *M. putrefaciens*

Although infections with *Mcc* and *M. putrefaciens* can be severe, their prevalence is relatively low and, as might be expected, little or no work appears to have been carried out on preventive vaccination for these infections.

REFERENCES

1. BASHIRUDDIN J.B., FREY J., KÖNIGSSON M.H., JOHANSSON K.-E., HOTZEL H., DILLER R., DE SANTIS P., BOTELHO A., AYLING R.D., NICHOLAS R.A.J., THIAUCOURT F. & SACHSE K. (2005). Evaluation of PCR systems for the identification and differentiation of *Mycoplasma agalactiae* and *Mycoplasma bovis*: A collaborative trial. *Vet. J.*, **169**, 268–275.
2. BASHIRUDDIN J.B., TAYLOR T.K. & GOULD A.R. (1994). A PCR-based test for the specific identification of *Mycoplasma mycoides* subsp. *mycoides* SC in clinical material. *J. Vet. Diagn. Invest.*, **6**, 428–434.
3. BERGONIER D., BERTHOLET X. & POUMARAT F. (1997). Contagious agalactia of small ruminants: current knowledge concerning epidemiology, diagnosis and control. *Rev. sci. tech. Off. int. Epiz.*, **16**, 848–873.
4. BOLSKE G., MSAMI H., HUMLESLO N.E., ERNO H. & JOHNSON L. (1988). *Mycoplasma capricolum* in an outbreak of polyarthritis and pneumonia in goats. *Acta Vet. Scand.*, **29**, 331–338.
5. BRADBURY J.M. (1998). Identification of mycoplasmas by immunofluorescence. *In: Mycoplasma Protocols*, Miles R.J. & Nicholas R.A.J., eds. Humana Press, Totowa, USA, 119–125.
6. DA MASSA A.J., BROOKS D.L. & ADLER H.E. (1983). Caprine mycoplasmosis: widespread infection in goats with *Mycoplasma mycoides* subsp. *mycoides* (large-colony type). *Am. J. Vet. Res.*, **44**, 322–325.
7. DEDIEU L., MADY V. & LEFEVRE P. C. (1995). Development of two PCRs for the identification of mycoplasmas causing contagious agalactia. *FEMS Microbiol. Lett.*, **129**, 243–250.
8. GRECO G., CORRENTE M., BUONOVOLIA D., ALIBERTI A. & FASANELLA A. (2002). Inactivated vaccine induces protection against *Mycoplasma agalactiae* infection in sheep. *Microbiologica*, **25**, 17–20.
9. GRECO G., CORRENTE M., MARTELLA V., PRATELLI A. & BOUNOVOLIA D. (2001). A multiplex PCR for the diagnosis of contagious agalactia of sheep and goats. *Mol. Cell. Probes*, **15**, 21–25.

10. GIL M.C., HERMOSA DE MENDOZA M., REY J., ALONSO J.M. POVEDA J.B. & HERMOSA DE MENDOZA J. (1999). Aetiology of caprine contagious agalactia syndrome in Extramadura, Spain. *Vet. Rec.*, **144**, 24–25.
11. KHAN L., LORIA G., ABU-AMERO K., NICHOLAS R.A.J., HALABLAB M. & MILES R.J. (2001). Distinctive biochemical characteristics of *Mycoplasma agalactiae* and *Mycoplasma bovis*. In: *Mycoplasmas of Ruminants: Pathogenicity, Diagnostics, Epidemiology and Molecular Genetics*, Vol. 5, Poveda J.B., Fernandez A., Frey J. & Johansson K.-E., eds. European Commission, Brussels, Belgium, 60–63.
12. KHAN L.A., LORIA G.R., RAMIREZ A.S., NICHOLAS R.A.J., MILES R.J. & FIELDER M.D. (2004). Biochemical characterisation of some non fermenting, non arginine hydrolysing mycoplasmas of ruminants. *Vet. Microbiol.*, **109**, 129–134.
13. LAMBERT M., CALAMEL M., DU FOUR P., CABASSE E., VITU C. & PEPIN M. (1998). Detection of false-positive sera in contagious agalactia with a multiantigen ELISA and their elimination with a protein G conjugate. *J. Vet. Diagn. Invest.*, **10**, 326–330.
14. LORIA G.R., SAMMARTINO C., NICHOLAS R.A.J. & AYLING R.D. (1999). *In vitro* susceptibility of field isolates of *Mycoplasma agalactiae* to oxytetracycline, tylosin, enrofloxacin, spiramycin and lincomycin-spectinomycin. *Res. Vet. Sci.*, **75**, 3–7.
15. MERCIER P., LENFANT D., POUMARAT F. & PERRIN G. (2001). Prevalence of mycoplasma infection within French milking caprine herds. In: *Mycoplasmas of Ruminants: Pathogenicity, Diagnostics, Epidemiology and Molecular Genetics*, Vol. 5, Poveda J.B., Fernandez A., Frey J. & Johansson K.-E., eds. European Commission, Brussels, Belgium, 130–133.
16. MCAULIFFE L., ELLIS R., LAWES J., AYLING R.D. & NICHOLAS R.A.J. (2005). 16S rDNA and DGGE: a single generic test for detecting and differentiating *Mycoplasma* species. *J. Med. Microbiol.*, **54**, 1–9.
17. NICHOLAS R.A.J. (1998). Surveillance for contagious agalactia in Great Britain. In: *Mycoplasmas of Ruminants: Pathogenicity, Diagnostics, Epidemiology and Molecular Genetics*, Vol. 2, Leori G., Santini F., Scanziani E. & Frey J., eds. European Commission, Brussels, Belgium, 95–97.
18. NICHOLAS R.A.J. (2002). Improvements in the diagnosis and control of diseases of small ruminants caused by mycoplasmas. *Small Rumin. Res.*, **45**, 145–149.
19. NICHOLAS R.A.J. & BAKER S.E. (1998). Recovery of mycoplasmas from animals. In: *Mycoplasma Protocols*, Miles R.J. & Nicholas R.A.J. eds. Humana Press, Totowa, USA, 37–44.
20. PEYRAUD A., WOUBIT S., POVEDA J.B., DE LA FE C., MERCIER P. & THIAUCOURT F. (2003). A specific PCR for the detection of *Mycoplasma putrefaciens*, one of the agents of the contagious agalactia syndrome of goats. *Mol. Cell. Probes*, **17**, 289–294.
21. POUMARAT F. (1998). Identification of mycoplasmas by dot immunobinding on membrane filtration (MF Dot). In: *Mycoplasma Protocols*, Miles R.J. & Nicholas R.A.J., eds. Humana Press, Totowa, USA, 113–118.
22. POVEDA J.B. (1998). Biochemical characteristics in mycoplasma identification. In: *Mycoplasma Protocols*, Miles R.J. & Nicholas R.A.J., eds. Humana Press, Totowa, USA, 69–78.
23. POVEDA J.B. & NICHOLAS R.A.J. (1998). Serological identification of mycoplasmas by growth and metabolic inhibition tests. In: *Mycoplasma Protocols*, Miles R.J. & Nicholas R.A.J., eds. Humana Press, Totowa, USA, 105–111.
24. RAMIREZ A S., DE LA FE C., ASSUNCAO P., GONZALEZ M. & POVEDA J.B. (2001). Preparation and evaluation of an inactivated polyvalent vaccine against *Mycoplasma* spp on infected goats. In: *Mycoplasmas of Ruminants: Pathogenicity, Diagnostics, Epidemiology and Molecular Genetics*, Vol. 5, Poveda J.B., Fernandez A., Frey J. & Johansson K.-E., eds. European Commission, Brussels, Belgium, 154–157.
25. RODRIGUEZ J.L., POVEDA J.B., GUTIERREZ C., ACOSTA B. & FERNANDEZ A. (1994). Polyarthritis in kids associated with *Mycoplasma putrefaciens*. *Vet. Rec.*, **135**, 406–407.
26. SUBRAHAMANIAM S., BERGONIER D., POUMARAT F., CAPUAL S., SCHLATTER Y., NICOLET J. & FREY J. (1998). Species identification of *Mycoplasma bovis* and *Mycoplasma agalactiae* based on the uvrC gene by PCR. *Mol. Cell. Probes*, **12**, 161–169.

27. SUNDER J., SRIVASTAVA N.C. & SINGH V.P. (2002) Preliminary trials on development of vaccine against *Mycoplasma mycoides* subsp. *mycoides* type LC infection in goats. *J. Appl. Anim. Res.*, **21**, 75–80.
28. TOLA S., ANGIOI A., ROCCHIGIANI A.M., IDINI G., MANUNTA D., GALLERI G. & LEORI G. (1997). Detection of *Mycoplasma agalactiae* in sheep milk samples by polymerase chain reaction. *Vet. Microbiol.*, **54**, 17–22.
29. TOLA S., MANUNTA D., COCCO M., TURRININ F., ROCCHIGIANI A.M., IDINI G., ANGIOI A. & LEORI G. (1997). Characterisation of membrane surface proteins of *Mycoplasma agalactiae* during natural infection. *FEMS Microbiol. Lett.*, **154**, 355–362.
30. TOLA S., MANUNTA D., ROCCA S., ROCCHIGIANI A.M., IDINI G., ANGIOI A. & LEORI G. (1999). Experimental vaccination of against *Mycoplasma agalactiae* using different inactivated vaccine. *Vaccine*, **17**, 2764–2768.

*
* *

NB: There is an OIE Reference Laboratory for contagious agalactia (see Table in Part 3 of this *Terrestrial Manual* or consult the OIE Web site for the most up-to-date list: www.oie.int).